Andrew A. F. Hack
CIK 1657434 · Chief Financial Officer · last filed 2026-01-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NUVL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Mersana Therapeutics, Inc. (MRSN) Delisted | Director | 0 | $29.08 | $0 | $48.36M | 22 | 2026-01-06 |
| Nuvalent, Inc. (NUVL) Delisted | Director | 1,449,766 | $123.96 | $179.71M | -$156.54M | 8 | 2024-12-13 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | 925,714 | $15.50 | $14.35M | -$151.66M | 15 | 2023-08-10 |
| Allena Pharmaceuticals, Inc. (ALNA) Delisted | Director | — | $0.07 | — | $0 | 3 | 2020-11-18 |
| AVIR | Director | 5,365,659 | $4.41 | $23.66M | $6.00M | 2 | 2020-11-03 |
| BCLS Acquisition Corp. (BLSA) Delisted | Chief Financial Officer | 487,500 | $10.04 | $4.89M | $0 | 1 | 2020-10-26 |
| EDIT | Chief Financial Officer | 0 | $2.75 | $0 | -$4.67M | 17 | 2019-02-06 |
Recent Filings · Page 3 of 7
69 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-26 | Mersana Therapeutics, Inc. (MRSN) Delisted | Buy (P) | +265,155 | $854.2K | EDGAR |
| 2022-05-23 | Mersana Therapeutics, Inc. (MRSN) Delisted | Buy (P) | +215,599 | $746.4K | EDGAR |
| 2022-05-18 | Mersana Therapeutics, Inc. (MRSN) Delisted | Buy (P) | +350,000 | $1.14M | EDGAR |
| 2022-04-14 | Mersana Therapeutics, Inc. (MRSN) Delisted | Buy (P) | +617,284 | $2.50M | EDGAR |
| 2022-04-13 | Mersana Therapeutics, Inc. (MRSN) Delisted | Buy (P) | +598,086 | $2.50M | EDGAR |
| 2022-02-08 | Mersana Therapeutics, Inc. (MRSN) Delisted | Buy (P) | +1,136,363 | $5.02M | EDGAR |
| 2022-01-05 | Mersana Therapeutics, Inc. (MRSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-04 | Mersana Therapeutics, Inc. (MRSN) Delisted | Buy (P) | +815,000 | $5.01M | EDGAR |
| 2022-01-03 | Mersana Therapeutics, Inc. (MRSN) Delisted | Buy (P) | +875,000 | $5.03M | EDGAR |
| 2021-08-27 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Mixed | −109,000 | -$32.44M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.